In parallel, Pagano et al. reported the findings from the PASADENA study where Prasinezumab (a monoclonal antibody directed against aggregated α-synuclein at the C-terminal of the protein, which may attenuate neurodegeneration by blocking the spread of pathogenic α-synuclein between neurons [6]) failed to slow down the PD disease progression over 52 weeks [7]. Here, SNCA is linked to Parkinson disease.